论文部分内容阅读
目的了解伏立康唑所致视觉障碍相关研究情况以及其临床病理特征,为临床安全使用伏立康唑提供参考。方法以“voriconazole”或“vfend”+视觉障碍表征词、“伏立康唑”+“不良反应”为检索词,检索PubMed、Embase、Web of Science、中国知网中国期刊全文数据库和中国生物医学文献数据库关于伏立康唑致视觉障碍的文献,对最终纳入分析的文献采用Excel表建立评价数据库,录入文献发表时间、文献类型、第一作者所在国家和机构、载文媒体及载文量、被引频次等文献计量学指标和伏立康唑致视觉障碍的临床表现、严重程度、预后、发生机制及防治措施等临床病理指标,并进行分析。结果共纳入文献119篇,其中英文文献92篇,中文文献27篇;论著61篇,综述36篇,病例报告17篇,会议论文5篇。国外和国内首次发表伏立康唑致视觉障碍文献的时间分别为1999和2008年。92篇英文文献第一作者所在地区依次为欧洲(33篇,35.9%)、北美洲(27篇,30.4%),亚洲(26篇,28.3%),大洋洲(5篇,5.4%)和南美洲(1篇,1.1%)。英文和中文文献最高被引频次分别1542和17次。伏立康唑致视觉障碍多发生在用药后第1周,静脉给药较口服给药更易引起视觉障碍。视觉障碍的主要临床表现为视物受干扰、非自主性眼球颤动、视力衰退、视觉变形、色觉改变、出现光点等,多数患者在1~3 d内可自行恢复正常视力。伏立康唑致视觉障碍的机制可能与视锥和视杆ON型双极细胞功能障碍有关。结论欧美国家对伏力康唑致视觉障碍的研究水平领先于我国,论著较综述有更广泛的影响力。伏立康唑引起的视觉障碍呈一过性和可逆性,临床应用比较安全。
Objective To understand the related research situation of voriconazole-induced visual impairment and its clinicopathological features and to provide a reference for the clinical use of voriconazole. Methods The search terms PubMed, Embase, Web of Science were searched with “voriconazole” or “vfend” + visual impairment indicator and “voriconazole” + “adverse reaction” Database and China Biomedical Literature Database on Vorconazole-induced visual impairment, the final inclusion of the literature using Excel tables to establish the evaluation database, entry documents published time, type of literature, the first author’s country and institutions, the media and the article Volume, cited bibliometrics and clinical manifestations of voriconazole-induced visual impairment, severity, prognosis, pathogenesis and prevention and treatment and other clinical and pathological indicators, and analysis. Results A total of 119 articles were included, of which 92 were in English and 27 in Chinese. There were 61 articles, 36 articles, 17 case reports and 5 conference papers. Foreign and domestic first published voriconazole-induced visual impairment of the literature in 1999 and 2008 respectively. The first authors of 92 English articles are followed by 33 (35.9%) in Europe, 27 in North America (30.4%), Asia (26 in 28.3%), Oceania (5 in 5.4%) and South America (1 article, 1.1%). The highest frequency of citation in English and Chinese was 1542 and 17 respectively. Voriconazole-induced visual impairment occurred in the first week after treatment, intravenous administration is more likely to cause visual impairment than oral administration. The main clinical manifestations of visual impairment as visual disturbances, involuntary eyeball fibrillation, visual acuity, visual distortion, color vision changes, the emergence of light spots, etc., most patients within 1 ~ 3 d can restore normal vision. The mechanism of voriconazole-induced visual impairment may be related to cone and rod ON-type bipolar cell dysfunction. Conclusion Europe and the United States lead to the level of visual impairment caused by voriconazole in our country, and the treatise has more extensive influence than the review. Voriconazole-induced visual impairment was transient and reversible, clinical application of safer.